



7 May 2013

ASX RELEASE

Novogen Announces New Executive Appointments

Novogen today announces two new executive appointments as part of its recent acceleration of its R&D programs and to support an expansion of the Company's activities into North America.

Dr David Brown has been appointed Chief Scientific Officer. David is a biologist who between 2000 and 2010 was responsible for the pre-clinical testing of Novogen oncology drugs including Phenoxodiol, Triphendiol, NV128, NV-143 and NV-344. In 2010, David left Novogen and joined Janssen as a Medical Advisor. He now returns to head up the Novogen R&D program. David will be based in Sydney. His role will be to oversee the pre-clinical development of the Company's drugs pipeline of CS-6 and two recently-identified lead drug candidates with a focus on melanoma and pancreatic cancer.

Dr Andrew Heaton has been appointed President and CEO of the Company's newly-established North American subsidiary, Novogen North America Inc. This wholly-owned subsidiary has been established to service the rapidly-expanding R&D and corporate activities of the Company in the US and Europe. Andrew will continue to oversee the Company's drug discovery program and the manufacture of drug ahead of clinical testing, both activities now centered in Europe. The Company is based in New York City and will provide a means to better interact with the Company's US-based shareholders who currently represent approximately 70% of the Company's share base, as well as the FDA and the SEC.

About Novogen

Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol 'NRT') and NASDAQ (symbol 'NVGN'). The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on comprehensive anti-cancer activity against both cancer cells and cancer stem cells. The Company's inaugural drug candidate is CS-6.

About CS-6

CS-6 belongs to a new class of drug candidates intended to treat most forms of cancer in a comprehensive manner, targeting both cancer cells and their progenitor cells, cancer stem cells. CS-6 shows broad anti-proliferative and cytotoxic activity against human cancer cells and ovarian cancer stem cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer.

Further information

Contact Dr Graham Kelly, Chief Executive Officer.

M: (61) 0459 200 095

E: Graham.Kelly@novogen.com

Please note that the Company currently is relocating offices and that the original phone numbers no longer are in use. New contact details will be available shortly.

Further information is available on the Company's web site, www.novogen.com